Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Let’s dig into the relative performance of Encompass Health (NYSE:EHC) and its peers as we unravel the now-completed Q2 outpatient & specialty care earnings season.
Health care services provider Encompass Health (NYSE:EHC) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 12% year on year to $1.46 billion. The company’s full-year revenue guidance of $5.93 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $1.40 per share was 15.8% above analysts’ consensus estimates.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Encompass Health (NYSE:EHC) and its peers.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
